Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 11.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1999 to 2008

Recipients with Heart Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 2,188 2,199 2,202 2,155 2,057 2,015 2,125 2,193 2,209 2,163
Tx with Follow-up Immunosuppression Info 1,769 1,811 1,848 1,817 1,734 1,741 1,802 1,888 1,901 1,803
Corticosteroids Any in Category 92.5% 92.2% 90.7% 88.3% 85.4% 89.8% 89.7% 88.9% 85.4% 79.5%
Steroids 92.5% 92.2% 90.7% 88.3% 85.4% 89.8% 89.7% 88.9% 85.4% 79.5%
Cyclosporine Any in Category 80.9% 76.8% 63.9% 56.9% 53.4% 49.1% 40.9% 38.0% 32.7% 23.6%
Cyclosporin 0.0% 0.0% 0.1% 0.1% 0.0% 0.1% 0.6% 1.3% 1.3% 1.3%
Sandimmmune 7.9% 5.5% 3.4% 2.0% 1.2% 1.3% 1.5% 1.8% 1.2% 0.4%
Neoral 73.0% 67.1% 50.3% 42.0% 38.2% 32.7% 27.1% 26.0% 23.5% 16.8%
Gengraf 0.0% 4.1% 9.7% 12.4% 13.4% 14.7% 11.3% 8.7% 6.4% 4.7%
Eon 0.1% 0.1% 0.3% 0.4% 0.6% 0.3% 0.4% 0.2% 0.4% 0.4%
Tacrolimus Any in Category 27.2% 30.6% 43.3% 50.0% 53.2% 57.0% 64.7% 67.5% 71.8% 77.0%
Tacrolimus 27.2% 30.6% 43.3% 50.0% 53.1% 57.0% 64.7% 67.1% 71.4% 76.5%
Everolimus 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.4% 0.4% 0.5%
Antimetabolites Any in Category 86.4% 90.9% 89.2% 87.4% 87.9% 94.4% 94.7% 92.6% 92.7% 89.6%
Mycophenolate Mofetil 57.5% 72.0% 74.8% 74.2% 78.1% 84.0% 82.5% 82.2% 81.1% 78.1%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.8% 0.3% 0.2% 2.7% 2.9% 5.0% 4.8%
Azathioprine 28.5% 18.7% 14.3% 12.3% 9.5% 10.2% 9.4% 7.3% 6.6% 6.7%
Leflunomide 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.2% 0.1% 0.0%
Cytoxan 0.3% 0.2% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitors Any in Category 3.2% 5.0% 7.4% 14.3% 16.4% 12.7% 11.0% 10.8% 10.4% 9.2%
Sirolimus 2.1% 4.7% 7.4% 14.3% 16.4% 12.6% 10.7% 8.7% 7.5% 7.9%
Everolimus 1.0% 0.3% 0.0% 0.0% 0.0% 0.1% 0.4% 2.0% 2.9% 1.3%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within

the same category.